【24h】

Computer Aided Clinical Trials for Implantable Cardiac Devices

机译:用于植入心脏装置的计算机辅助临床试验

获取原文

摘要

In this paper we aim to answer the question, "How can modeling and simulation of physiological systems be used to evaluate life-critical implantable medical devices?" Clinical trials for medical devices are becoming increasingly inefficient as they take several years to conduct, at very high cost and suffer from high rates of failure. For example, the Rhythm ID Goes Head-to-head Trial (RIGHT) sought to evaluate the performance of two arrhythmia discriminator algorithms for implantable cardioverter defibrillators, Vitality 2 vs. Medtronic, in terms of time-to-first inappropriate therapy, but concluded with results contrary to the initial hypothesis - after 5 years, 2,000+ patients and at considerble ethical and monetary cost. In this paper, we describe the design and performance of a Computer-aided Clinical Trial (CACT) for Implantable Cardiac Devices where previous trial information, real patient data and closed-loop device models are effectively used to evaluate the trial with high confidence. We formulate the CACT in the context of RIGHT using a Bayesian statistical framework. We define a hierarchical model of the virtual cohort generated from a physiological model which captures the uncertainty in the parameters and allow for the systematic incorporation of information available at the design of the trial. With this formulation, the estimates the inappropriate therapy rate of Vitality 2 compared to Medtronic as 33.22% vs 15.62% (p<0.001), which is comparable to the original trial. Finally, we relate the outcomes of the computer-aided clinical trial to the primary endpoint of RIGHT.
机译:在本文中,我们的目标是回答问题,“如何使用生理系统的建模和仿真来评估寿命植入的医疗设备?”医疗器械的临床试验随着几年的时间而越来越低,以非常高的成本,并且遭受高失败率。例如,节奏ID前往头部试验(右)试图评估两个心律失常鉴别器算法的性能,用于植入的心脏除颤器,活力2与Medtronic的活力2对塞进,但总结一下结果与初步假设相反 - 5年后,2,000多名患者和伦理和货币成本。在本文中,我们描述了用于可植入的心脏装置的计算机辅助临床试验(CACT)的设计和性能,其中植入信息,真实的患者数据和闭环装置模型有效地用于评估高度置信度的试验。我们在使用贝叶斯统计框架的权利上制定了CACT。我们定义了从生理模型产生的虚拟群组的分层模型,该模型捕获参数中的不确定性,并允许系统纳入试验设计中可用的信息。通过这种制剂,与Medtronic相比,估计活力2的治疗率为33.22%与15.62%(p <0.001)相比,这与原始试验相当。最后,我们将计算机辅助临床试验的结果与右边的主要终点相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号